This study will observe the degree of the quality of life in non-transplant candidate
patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ
C30 (European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions). Both tools are validated research
instruments used to measure the quality of life in cancer patients and consequently will
provide fundamental data regarding the quality of life in patients with multiple myeloma by
analyzing factors that affect the quality of life.